Replies to post #240903 on Biotech Values

[swampboots]

GNCA .95 cent bet, mentioned in that summary?

"Genocea Biosciences’s GEN-009 vaccine trial (NCT03633110) is one of the few Phase 1/2a clinical trials that have shown the best efficacy among the current neoantigen personalization therapies with an estimated completion date of December 2022. The purpose of this study was to evaluate the safety, tolerability, immunogenicity, and antitumor activity of the personalized vaccine GEN-009 for the treatment of patients with solid tumors, which is targeted at a broad range of cancers. The results so far show that 40 doses of the vaccine have been administered, and only a few patients have experienced mild local discomfort caused by the vaccine adjuvant with no dose limited toxicity (DLT) occurred. Ninety-nine percent of the peptides selected for the vaccine produce an immune response, and so far, no patients who have received the vaccine have relapsed (73, 89)."

[db7]

MSKCC(?), ID proteins; looks like this outfit is about to file an IND and mentions raising money soon

https://www.angiogenex.com/about/


"Together with Angiogenex, Inc. Dr Robert Benezra, Member of the Cancer Biology and Genetics Program at Memorial Sloan Kettering Cancer Center, has identified a small molecule, AGX51, that inhibits ID proteins and disrupts the cellular pathways by which cancers repropagate, and could..."

I have a small token position from awhile back just to track their progress; at the moment the stock doesn't even trade fwiw...